Abiomed (ABMD) is strategically focused on the market penetration of the company’s family of Impella heart pumps. The Impella device portfolio consists of Impella 2.5, Impella CP, Impella RP, Impella LD, and Impella 5.0 devices. To this end, Abiomed discontinued the sale of its AB5000 device used for heart surgery.
The Impella RP heart pump received Food and Drug Administration (or FDA) PMA approval in September 2017 for providing temporary right ventricular support for up to 14 days to patients who develop right heart failure.
Abiomed’s Impella 5.5 device is a micro heart pump with integrated motors and sensors and provides months of hemodynamic support. Abiomed expects to conduct the first trial of the device outside of the US in 2018.
Abiomed’s Impella ECP pump is designed to provide blood flow of over three liters per minute and is intended to be delivered on a standard-sized catheter. Abiomed expects to conduct a first in man trial of the pump outside of the US in 2018.
Abiomed’s Impella BTR device is designed to provide up to one year of hemodynamic support and allow for more than five liters of blood flow per minute. The device includes a wearable driver designed for hospital discharge.
Research and development expenses
In fiscal 2018 and 2019, Abiomed is expected to incur research and development expenses of $75 million and $94.7 million, respectively, while peers Baxter International (BAX), Insulet (PODD), and NxStage Medical (NXTM) are expected to incur R&D expenses of $626.9 million, $84 million, and $40.8 million, respectively.
In the next part of the series, we’ll take a look at the financial performance of Abiomed.